Last reviewed · How we verify

E2 patch/antagonist — Competitive Intelligence Brief

E2 patch/antagonist (E2 patch/antagonist) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen receptor antagonist / hormone replacement therapy. Area: Endocrinology / Women's Health.

marketed Estrogen receptor antagonist / hormone replacement therapy Estrogen receptor (ER-α, ER-β) Endocrinology / Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

E2 patch/antagonist (E2 patch/antagonist) — Weill Medical College of Cornell University. An estradiol (E2) transdermal patch that delivers estrogen while blocking estrogen receptor signaling through an antagonist component.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
E2 patch/antagonist TARGET E2 patch/antagonist Weill Medical College of Cornell University marketed Estrogen receptor antagonist / hormone replacement therapy Estrogen receptor (ER-α, ER-β)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Estrogen receptor antagonist / hormone replacement therapy class)

  1. Weill Medical College of Cornell University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). E2 patch/antagonist — Competitive Intelligence Brief. https://druglandscape.com/ci/e2-patch-antagonist. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: